AIM: To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients. METHODS: Out of 1228 CHC patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV), 165 (13%) had a relapse. Among these, 62 patients were retreated with PEG-IFN-α2a or -α2b and RBV. Clinical, biological, virological and histological data were collected. Initial doses and treatment modifications were recorded. The efficacy of retreatment and predictive factors for SVR were analyzed. RESULTS: An SVR was achieved in 42% of patients. SVR was higher in young (< 50 years) (61%) than old patients (27%) (P = 0.007), and in genotype 2 or 3 (57%) than in genotype 1 or 4 (28%) patients (P = 0.023). Prolonging therapy for at least 24 wk more than the previous course was associated with higher SVR rates (53% vs 28%, P = 0.04). Also, a better SVR rate was observed with RBV dose/body weight > 15.2 mg/kg per day (70% vs 35%, P = 0.04). In logistic regression, predictors of a response were age (P = 0.018), genotype (P = 0.048) and initial RBV dose/body weight (P = 0.022). None of the patients without a complete early virological response achieved an SVR (negative predictive value = 100%). CONCLUSION: Retreatment with PEG-IFN/RBV is eff-ective in genotype 2 or 3 relapsers, especially in young patients. A high dose of RBV seems to be important for the retreatment response.
AIM: To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients. METHODS: Out of 1228 CHCpatients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV), 165 (13%) had a relapse. Among these, 62 patients were retreated with PEG-IFN-α2a or -α2b and RBV. Clinical, biological, virological and histological data were collected. Initial doses and treatment modifications were recorded. The efficacy of retreatment and predictive factors for SVR were analyzed. RESULTS: An SVR was achieved in 42% of patients. SVR was higher in young (< 50 years) (61%) than old patients (27%) (P = 0.007), and in genotype 2 or 3 (57%) than in genotype 1 or 4 (28%) patients (P = 0.023). Prolonging therapy for at least 24 wk more than the previous course was associated with higher SVR rates (53% vs 28%, P = 0.04). Also, a better SVR rate was observed with RBV dose/body weight > 15.2 mg/kg per day (70% vs 35%, P = 0.04). In logistic regression, predictors of a response were age (P = 0.018), genotype (P = 0.048) and initial RBV dose/body weight (P = 0.022). None of the patients without a complete early virological response achieved an SVR (negative predictive value = 100%). CONCLUSION: Retreatment with PEG-IFN/RBV is eff-ective in genotype 2 or 3 relapsers, especially in young patients. A high dose of RBV seems to be important for the retreatment response.
Authors: Mitchell L Shiffman; Jennifer Salvatore; Sarah Hubbard; Angie Price; Richard K Sterling; R Todd Stravitz; Velimir A Luketic; Arun J Sanyal Journal: Hepatology Date: 2007-08 Impact factor: 17.425
Authors: Ira M Jacobson; Stevan A Gonzalez; Furqaan Ahmed; Edward Lebovics; Albert D Min; Henry C Bodenheimer; Stephen P Esposito; Robert S Brown; Norbert Bräu; Franklin M Klion; Hillel Tobias; Edmund J Bini; Neil Brodsky; Maurice A Cerulli; Ayse Aytaman; Peter W Gardner; Jane M Geders; Julie E Spivack; Michael G Rahmin; David H Berman; James Ehrlich; Mark W Russo; Maxwell Chait; Deborah Rovner; Brian R Edlin Journal: Am J Gastroenterol Date: 2005-11 Impact factor: 10.864
Authors: Mitchell L Shiffman; Marc G Ghany; Timothy R Morgan; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Jules L Dienstag; David R Gretch Journal: Gastroenterology Date: 2006-11-11 Impact factor: 22.682
Authors: E Parise; H Cheinquer; D Crespo; A Meirelles; A Martinelli; H Sette; J Gallizi; R Silva; C Lacet; E Correa; H Cotrim; J Fonseca; R Paraná; V Spinelli; W Amorim; F Tatsch; M Pessoa Journal: Braz J Infect Dis Date: 2006-06-02 Impact factor: 1.949
Authors: M Basso; F Torre; A Grasso; G Percario; E Azzola; S Artioli; S Blanchi; N Pelli; A Picciotto Journal: Dig Liver Dis Date: 2006-10-31 Impact factor: 4.088
Authors: V G Bain; S S Lee; K Peltekian; E M Yoshida; M Deschênes; M Sherman; R Bailey; H Witt-Sullivan; R Balshaw; M Krajden Journal: Aliment Pharmacol Ther Date: 2008-04-07 Impact factor: 8.171